View Older Stories View More Recent Stories

Mar 23, 2020 08:00AM AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Mar 17, 2020 04:31PM AbbVie (ABBV), Allergan (AGN) Sign Consent Decree Agreement with FTC Staff on Pending Transaction
Mar 17, 2020 04:30PM AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
Mar 12, 2020 07:01AM AbbVie (ABBV) Receives EC Approval of VENCLYXTO Combination Regimen for Patients with Previously-Untreated CLL
Mar 12, 2020 07:00AM AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Mar 9, 2020 08:45AM AbbVie (ABBV) Says It's Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19
Mar 9, 2020 08:45AM AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19
Mar 6, 2020 07:01AM AbbVie (ABBV) Announces EC Grants Marketing Authorization Shortening MAVIRET Treatment Duration to Eight Weeks for Some HCV Patients
Mar 6, 2020 07:00AM European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 an
Mar 3, 2020 08:01AM AbbVie (ABBV), Allergan Receive Final European Approval to Close Pending Transaction
Mar 3, 2020 08:00AM AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
Mar 2, 2020 05:54AM AbbVie (ABBV) Reports Update from Ph. 3 Study Evaluating VENCLEXTA (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with AML
Feb 28, 2020 06:53PM AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)
Feb 20, 2020 01:14PM AbbVie Declares Quarterly Dividend
Feb 19, 2020 08:00AM AbbVie to Present at the Cowen 40th Annual Health Care Conference
Feb 11, 2020 08:00AM AbbVie to Present at the SVB Leerink 9th Annual Global Healthcare Conference
Feb 7, 2020 07:43AM AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results
Feb 6, 2020 01:07AM Desperate for coronavirus solutions, Chinese turn to HIV drugs, gray market and traditional cures
Feb 5, 2020 08:45AM AbbVie (ABBV) Announces RINVOQ Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
Feb 5, 2020 08:45AM RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
Jan 31, 2020 07:17AM AbbVie (ABBV) Receives Positive CHMP Opinion for MAVIRET to Shorten Treatment to Eight Weeks in GT 3 HCV and Compensated Cirrhosis
Jan 31, 2020 07:15AM AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compen
Jan 31, 2020 06:57AM AbbVie (ABBV) Receives Positive CHMP Opinion for VENCLYXTO as Chemotherapy-Free Combination Regimen for Patients with Previously Untreated CLL
Jan 31, 2020 06:55AM AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Jan 27, 2020 05:57AM AbbVie (ABBV), Allergan (AGN) Report Agreements to Divest Brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase)
Jan 27, 2020 01:15AM AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
Jan 14, 2020 08:46AM AbbVie (ABBV) Announces New Head-to-Head Phase 3 Data Show SKYRIZI Superior to Cosentyx Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
Jan 14, 2020 08:45AM New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis a
Jan 13, 2020 08:00AM AbbVie to Host Fourth-Quarter and Full-Year 2019 Earnings Conference Call
Jan 8, 2020 08:08AM AbbVie (ABBV) Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition
Jan 8, 2020 08:00AM AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition
Jan 3, 2020 08:00AM AbbVie to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 18, 2019 10:52AM AbbVie (ABBV) Granted EC Approval of RINVOQ for Rheumatoid Arthritis
Dec 18, 2019 10:50AM AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Dec 9, 2019 08:08AM AbbVie (ABBV), Scripps Research announce collaboration to develop broad range of new therapeutics
Dec 9, 2019 08:00AM AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics
Dec 9, 2019 06:08AM AbbVie (ABBV) Reports Extended Follow-up Ph. 3 Data Underscore Sustained Efficacy & Safety of IMBRUVICA (ibrutinib) in Treatment of CLL
Dec 8, 2019 07:30AM New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic
Dec 7, 2019 09:00AM More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Un
Dec 7, 2019 07:33AM Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Dec 7, 2019 07:30AM IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
Dec 3, 2019 05:00AM Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone
Nov 21, 2019 08:34AM AbbVie (ABBV) to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at ASH
Nov 21, 2019 08:30AM AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting
Nov 21, 2019 06:19AM Harpoon Therapeutics Inc. (HARP), AbbVie (ABBV) Report Licensing & Option Collaboration to Advance HPN217
Nov 21, 2019 04:00AM Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
Nov 21, 2019 04:00AM Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
Nov 20, 2019 08:00AM Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology
Nov 12, 2019 11:16AM AbbVie (ABBV) Announces New Positive Data for RINVOQ on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at ACR/ARP
Nov 12, 2019 11:15AM New Positive Data for RINVOQ™ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting
View More Recent Stories View Older Stories